IOMMELLI, FRANCESCA
 Distribuzione geografica
Continente #
AS - Asia 1.565
NA - Nord America 785
EU - Europa 402
SA - Sud America 216
AF - Africa 16
OC - Oceania 1
Totale 2.985
Nazione #
US - Stati Uniti d'America 742
SG - Singapore 632
CN - Cina 331
HK - Hong Kong 268
BR - Brasile 172
VN - Vietnam 130
IT - Italia 127
FR - Francia 91
JP - Giappone 58
KR - Corea 57
NL - Olanda 54
FI - Finlandia 35
DE - Germania 30
GB - Regno Unito 22
IN - India 21
AR - Argentina 19
CA - Canada 19
BD - Bangladesh 15
MX - Messico 14
EC - Ecuador 9
IQ - Iraq 8
CO - Colombia 7
ES - Italia 7
IL - Israele 7
RU - Federazione Russa 7
ZA - Sudafrica 7
ID - Indonesia 6
IE - Irlanda 5
TR - Turchia 5
KH - Cambogia 4
UA - Ucraina 4
UZ - Uzbekistan 4
AT - Austria 3
JO - Giordania 3
LV - Lettonia 3
SA - Arabia Saudita 3
VE - Venezuela 3
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
MA - Marocco 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
PK - Pakistan 2
PL - Polonia 2
SE - Svezia 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BB - Barbados 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
GP - Guadalupe 1
HN - Honduras 1
IM - Isola di Man 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LT - Lituania 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
TH - Thailandia 1
Totale 2.985
Città #
Singapore 396
Santa Clara 287
Hong Kong 267
Hefei 115
San Jose 103
Beijing 90
Lauterbourg 68
Ashburn 67
Seoul 57
Naples 55
Tokyo 50
Ho Chi Minh City 47
Hanoi 33
Los Angeles 28
New York 18
Lappeenranta 17
São Paulo 17
Frankfurt am Main 15
Helsinki 14
Casandrino 13
Buffalo 9
Council Bluffs 9
Dallas 8
Brooklyn 7
Orem 7
Rome 7
Belleville 6
Bengaluru 6
Mexico City 6
Minamishinagawa 6
Rio de Janeiro 6
Belo Horizonte 5
Boardman 5
Chicago 5
Da Nang 5
Des Moines 5
Dublin 5
Hangzhou 5
London 5
Milan 5
Amsterdam 4
Baghdad 4
Buenos Aires 4
Carapicuíba 4
Düsseldorf 4
Ercolano 4
Guayaquil 4
Istanbul 4
Phnom Penh 4
Poplar 4
Porto Alegre 4
Tashkent 4
Turku 4
Atlanta 3
Biên Hòa 3
Can Tho 3
Chennai 3
Duque de Caxias 3
Ha Long 3
Haiphong 3
Johannesburg 3
Miami 3
Munich 3
Paris 3
Phoenix 3
Phủ Lý 3
Quito 3
Riga 3
Salvador 3
Shanghai 3
Vitória da Conquista 3
Abidjan 2
Amman 2
Baku 2
Bauru 2
Bonito 2
Boston 2
Brasília 2
Bratislava 2
Chongqing 2
City of London 2
Dhaka 2
Elk Grove Village 2
Erbil 2
Falkenstein 2
Fortaleza 2
Franco da Rocha 2
Guangzhou 2
Houston 2
Hyderabad 2
Hòa Bình 2
Hải Dương 2
Joinville 2
Juiz de Fora 2
Lajeado 2
Lima 2
Madrid 2
Manchester 2
Manila 2
Medellín 2
Totale 2.043
Nome #
Monitoring Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by 18F-FLT PET/CT 76
18F-FLT PET/CT imaging and inhibition of multiple signaling pathways downstream EGFR and MET receptors in resistant NSCLC 74
Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides 72
ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors 68
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 67
Gefitinib, a selective, tyrosine kinase inhibitor increases 99mTc-MIBI uptake in Bcl-2 overexpressing breast cancer cells. 65
Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by F-18-fluorothymidine 65
Molecular mechanisms of decreased aerobic glycolysis in non-small lung cancer treated with EGFR tyrosine kinase inhibitors. European Society for Molecular Imaging Meeting 65
Changes of Glycolytic Pathway in Response to Efficient Inhibition of EGFR Signaling in Non-small Cell Lung Cancer (NSCLC) 64
Multimodal imaging of tumor invasion by targeting integrin ?v?3 in a preclinical model of lung metastasis 63
18F-FLT PET/CT for Detection of Functional Cross-talk between MET and EGFR in Non-small Cell Lung Cancer Resistant to EGFR Inhibitors 62
Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy 61
Changes of glycolytic pathway and upregulation of oxidative phosphorylation in BCR-ABL-driven human leukemia cells treated with imatinib 60
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 59
Exosome-like Systems: From Therapies to Vaccination for Cancer Treatment and Prevention-Exploring the State of the Art 58
Early reduction of 18F-FDG uptake in non-small lung cancer treated with EGFR tyrosine kinase inhibitors reflects reversal of Warburg effect and reactivation of oxidative phosphorylation. 56
Imaging of alpha(v)beta(3) integrin expression with a 18F-labeled RGD peptide and microPET 55
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 55
New and selective radiolabeled alpha(v)beta(3) antagonist as tracer in tumor diagnosis 54
Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells 54
Preclinical imaging for targeting cancer immune evasion 52
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 52
A reversible shift of driver dependence from egfr to notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors 51
Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells 51
Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER–Mitochondria Interface in Oncogene-Driven NSCLC 49
18F-FLT PET/CT to guide therapy with EGFR antagonists and Bcl-xL inhibitors in non-small cell lung cancer. 45
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 43
Preclinical Imaging in Targeted Cancer Therapies 43
Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins 43
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer 43
Monitoring the effects of combined treatment with EGFR and MET inhibitors in non-small cell lung cancer and synergy quantification by 18F-FLT PET/CT 42
Notch1-dependent targets in cancer stem cell resistance to EGFR inhibitors in oncogene-driven non-small cell lung cancer 42
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells 41
PET/CT in cancer research: from preclinical to clinical applications 40
IN VIVO IMAGING OF ALPHA(V)BETA(3) INTEGRIN EXPRESSION WITH A RADIOLABELED CHIMERIC RDG PEPTIDE 40
Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors 38
99mTc-MIBI in the evaluation of breast cancer biology 38
18F-FLT PET/CT imaging of inositol trisphosphate receptor type 3-mediated enhancement of EGFR and MET co-targeting efficacy in non-small cell lung cancer 37
Preclinical imaging in oncology: advances and perspectives 37
18F-FLT PET/CT as a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 36
Early F-18-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 35
Imaging of alpha(v)beta(3) Expression by a Bifunctional Chimeric RGD Peptide not Cross-Reacting with alpha(v)beta(5) 34
18F-FLT PET/CT to Detect Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer. 33
Novel and selective αvβ3 receptor peptide antagonist: Design, synthesis, and biological behavior 32
99mTc-MIBI in the evaluation of breast cancer biology 31
Evaluation of experimental pulmonary metastases in murine models by x-ray micro-computed tomography 31
Effect of IL-1β on NSCLC-Derived Small Extracellular Vesicles as Actors in Mediating Cancer Progression and Evading Immune System 30
In vivo imaging of alpha(v)beta(3) integrin expression with a radiolabeled chimeric RGD peptide 30
Molecular imaging of drug resistance in cancer 30
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography 29
A RADIOLABELING SYNTHESIS OF RGD ECHI WITH 18FLUORIDE- 28
Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors 28
18F-FLT PET/CTas a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 28
Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. 28
18F-FLT PET/CT to guide therapy with EGFR antagonists and Bcl-xL inhibitors in non-small cell lung cancer 27
MicroPET/CT of mice bearing alpha(v)beta(3)-expressing tumors by a 18F-labeled bifunctional chimeric RGD peptide 27
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-X-L modulation of inositol trisphosphate receptor type 3 27
IMAGING IN VIVO DELL'ESPESSIONE DELL'INTEGRINA alfa(v)beta(3) CON UN PEPTIDE CHIMERICO RGD RADIOMARCATO 27
Stato dell'arte dell'imaging preclinico in oncologia 27
Imaging of alpha(v)beta(3) integrin expression with a 18F-labeled RGD peptide and microPET 27
18F-FLT PET/CT to detect reversal of EGFR TKI resistance due to MET amplification by MET inhibitors in NSCLC 27
18F-FLT PET/CT to Detect Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer 26
Combined Imaging with 18F-FLT PET/CT and 99m-Tc-Hynic-Annexin V SPECT for Personalized Therapy with EGFR Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer 26
[18]F-FLT PET-CT to detect reversal of EGFR TKI resistance due to MET amplification by MET inhibitors in NSCLC. 26
Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer 24
PET/CT in cancer research: from preclinical to clinical applications 23
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 23
New and selective radiolabeled alphavbeta3 peptide antagonist as tracer in tumor diagnosis 23
Effect of Soluble Factors Released from Porcine Freeze-Dried Lung Tissue (FDLT) on Modulation of Cell Growth and EMT Signature in Non-Small Cell Lung Cancer (NSCLC)—A Preliminary In Vitro Study 22
Neutrophil extracellular traps as drivers of epithelial-mesenchymal transition in cancer cells 22
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 22
Molecular imaging of tumor microenvironment: challenges and perspectives 21
Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in NSCLC 21
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 17
Synergistic effects of oncogene inhibition and pyruvate dehydrogenase kinase blockade in resistant NSCLC cells 16
Addition of metformin to anti-PD-1/PD-L1 drugs activates antitumor immune response in peripheral immune cells of NSCLC patients 15
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood 12
Totale 3.071
Categoria #
all - tutte 9.434
article - articoli 7.686
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 220
Totale 17.340


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202445 0 0 0 0 0 0 0 0 4 13 13 15
2024/20251.214 14 13 106 58 293 51 14 73 59 79 239 215
2025/20261.812 95 151 121 204 430 105 281 78 149 125 73 0
Totale 3.071